Skip to main content
SpringerLink
Log in

The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease

  • Original Article
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

A Correction to this article was published on 05 February 2021

This article has been updated

Abstract

Background

Resistance to antiplatelet therapy, especially aspirin or clopidogrel, triggers other therapies for patients with coronary heart disease (CHD). Enhanced external counterpulsation (EECP) is a noninvasive, pneumatic technique that provides beneficial effects for patients with CHD. However, the physiological effects of EECP have not been fully studied, and the role of EECP on platelet function remains poorly understood.

Methods

A total of 168 patients with CHD were finally selected from the Second Xiangya Hospital and randomly assigned to either a control group or EECP group. The control group accepted only standard medical treatment, while the EECP group accepted standard medical treatment and EECP treatment. Blood samples were collected from patients at baseline and after EECP, and platelet aggregation was assessed. Changes in platelet aggregation were compared before and after treatment.

Results

There was no difference in the basal levels of arachidonic acid (AA) induced platelet maximum aggregation ratio (MAR) between the two groups. The AA-induced platelet MAR was significantly decreased after EECP therapy. The logistic analysis showed that low HDL-C was not favorable for the decrease in platelet aggregation.

Conclusion

EECP therapy is favorable for lowering platelet aggregation in patients with CHD, especially the AA-induced platelet aggregation ratio.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

Abbreviations

CHD:

Coronary heart disease

LDL-C:

Low-density lipoprotein cholesterol

HDL-C:

High-density lipoprotein cholesterol

MAR:

Maximum aggregation ratio

BMI:

Body mass index

ACS:

Acute coronary syndromes

References

  1. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  2. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–8.

    Article  Google Scholar 

  3. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593–9.

    Article  Google Scholar 

  4. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–60.

    Article  Google Scholar 

  5. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51:1829–43.

    Article  CAS  Google Scholar 

  6. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–17.

    Article  CAS  Google Scholar 

  7. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet. 2009;373:1849–60.

    Article  Google Scholar 

  8. Antithrombotic Trialists’ Collaboration. Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  9. Hovens MM, Snoep JD, Eikenboom JC, et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153(2):175–81.

    Article  CAS  Google Scholar 

  10. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–13.

    Article  Google Scholar 

  11. Hennekens CH, Schror K, Weisman S, et al. Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004;110:1706–8.

    Article  Google Scholar 

  12. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246–51.

    Article  CAS  Google Scholar 

  13. Michaels AD, Accad M, Ports TA, et al. Left ventricular systolic unloading and augmentation of intracoronary pressure and Doppler flow during enhanced external counterpulsation. Circulation. 2002;106:1237–42.

    Article  Google Scholar 

  14. Manchanda A, Soran O. Enhanced external counterpulsation and future directions: step beyond medical management for patients with angina and heart failure. J Am Coll Cardiol. 2007;50:1523–31.

    Article  Google Scholar 

  15. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33:1833–40.

    Article  CAS  Google Scholar 

  16. Guan J, Cong Y, Ren J, et al. Comparison between a new platelet count drop method PL-11, light transmission aggregometry, VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals. Platelets. 2015;26(1):25–30.

    Article  CAS  Google Scholar 

  17. Bonetti PO, Barsness GW, Keelan PC, et al. Enhanced external counterpulsation inproves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol. 2003;41:1761–8.

    Article  Google Scholar 

  18. Casey DP, Conti CR, Nichols WW, et al. Effect of enhanced external counterpulsation on inflammatory cytokines and adhesion molecules in patients with angina pectoris and angiographic coronary artery disease. Am J Cardiol. 2008;101:300–2.

    Article  CAS  Google Scholar 

  19. Rubenstein DA, Yin W. Quantifying the effects of shear stress and shear exposure duration regulation on flow induced platelet activation and aggregation. J Thromb Thrombolysis. 2002;30:36–45.

    Article  Google Scholar 

  20. Sheriff J, Bluestein D, Girdhar G, et al. High-shear stress sensitizes platelets to subsequent low-shear conditions. Ann Biomed Eng. 2010;38:1442–50.

    Article  Google Scholar 

  21. Yin W, Shanmugavelayudam SK, Rubenstein DA. The effect of physiologically relevant dynamic shear stress on platelet and endothelial cell activation. Thromb Res. 2011 Mar;127(3):235–41.

    Article  CAS  Google Scholar 

  22. Jastrzebska M, Chelstowski K, Wodecka A, et al. Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. Blood Coagul Fibrinolysis. 2013;24(8):830–8.

    Article  CAS  Google Scholar 

  23. Yeung J, Tourdot BE, Fernandez-Perez P, et al. Platelet 12-LOX is essential for FcγRIIa-mediated platelet activation. Blood. 2014;124(14):2271–9.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all patients who participated in this study, Xiaoxiu Wang for platelet aggregation ratio measurement, and the Department of Clinical Laboratory, Second Xiangya Hospital, for their assistance.

Availability of Data and Material

Some restrictions will apply.

Funding

This work was supported by National Nature Scientific Funding of China (No. 81672264), and the Fundamental Research Funds for the Central Universities of Central South University (No.2018zzts260).

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    Yating Wang & Danyan Xu

Authors
  1. Yating Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danyan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Yating Wang and Danyan Xu designed the study, analyzed the data, and prepared the manuscript.

Corresponding author

Correspondence to Danyan Xu.

Ethics declarations

Declarations

Not applicable.

Conflict of Interest

The authors declare no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: Originally, the article was published electronically on the publisher’s internet portal (currently SpringerLink) on 21 January 2021 with open access.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Xu, D. The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease. Cardiovasc Drugs Ther 36, 263–269 (2022). https://doi.org/10.1007/s10557-020-07140-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-020-07140-4

Keywords

Search

Navigation